KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Account Payables (2016 - 2020)

Supernus Pharmaceuticals (SUPN) has disclosed Change in Account Payables for 7 consecutive years, with $5.7 million as the latest value for Q3 2020.

  • Quarterly Change in Account Payables rose 564.92% to $5.7 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $5.8 million through Sep 2020, up 182.67% year-over-year, with the annual reading at $7.0 million for FY2019, 294.58% up from the prior year.
  • Change in Account Payables for Q3 2020 was $5.7 million at Supernus Pharmaceuticals, up from -$182000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $7.3 million in Q4 2019, with the low at -$7.0 million in Q1 2020.
  • Average Change in Account Payables over 5 years is $247736.8, with a median of -$380000.0 recorded in 2016.
  • The sharpest move saw Change in Account Payables skyrocketed 937.63% in 2017, then plummeted 1060.12% in 2018.
  • Over 5 years, Change in Account Payables stood at $5.1 million in 2016, then plummeted by 86.43% to $692000.0 in 2017, then tumbled by 1060.12% to -$6.6 million in 2018, then skyrocketed by 209.81% to $7.3 million in 2019, then decreased by 22.26% to $5.7 million in 2020.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $5.7 million, -$182000.0, and -$7.0 million for Q3 2020, Q2 2020, and Q1 2020 respectively.